Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
A Pilot Study of MR Imaging With Ultra-small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition
Sponsor: Princess Margaret Hospital, Canada
A PHASE1/PHASE2 clinical study on Bladder Neoplasms and Cervix Neoplasms, this trial is completed. The trial is conducted by Princess Margaret Hospital, Canada and has accumulated 9 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
May 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2021 — May 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
May 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Completed → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Princess Margaret Hospital, Canada
- University Health Network, Toronto
For direct contact, visit the study record on ClinicalTrials.gov .